Seasonal influenza vaccination in Europe
This report summarises information on seasonal influenza immunisation recommendations and vaccination coverage rates in the EU/EEA between 2007–08 and 2014–15.
In Europe, influenza occurs in regular annual epidemics in the winter season. Annual influenza epidemics are associated with high morbidity and mortality. Severe illness and complications are more common in certain risk groups, which include those with chronic medical conditions (e.g. cardiovascular, respiratory, renal and hepatic diseases; diabetes mellitus; immunosuppression due to disease or treatment; obesity; children and teenagers on long-term aspirin therapy) and individuals 65 years of age and above. The main public health intervention to prevent influenza is vaccination. To protect vulnerable individuals and reduce transmission, vaccination is also recommended for healthcare workers.
The aim of this report was to summarise the information on seasonal influenza immunisation recommendations and vaccination coverage rates in the European Union (EU) and the European Economic Area (EEA) between 2007– 08 and 2014–15, a total of eight influenza seasons.
See all updates on seasonal influenza immunisation
Universal influenza vaccine candidates provide heterosubtypic protection in mice, ferrets and non-human primates
Seasonal influenza vaccination recommendations and coverage rates, 2012/13 - Country profile for Greece
Seasonal influenza vaccination recommendations and coverage rates, 2012/13 - Country profile for Slovakia
Related diseases and public health areas
Seasonal influenza is a preventable infectious disease with mostly respiratory symptoms. It is caused by influenza virus and is easily transmitted, predominantly via the droplet and contact routes and by indirect spread from respiratory secretions on hands etc.Read more
Communication toolkit on influenza immunisation
This toolkit aims to assist EU Member States in devising communication activities to increase influenza vaccination uptake and promote preventive measures to limit its spread. It can be adapted and used by countries that have not yet developed specific health communication programmes or as a bank of ideas.Read more